Illumina’s Early Deal Close Draws EU ‘Interim Measures’

By Bryan Koenig (September 20, 2021, 5:16 PM EDT) — European Union antitrust officials moved Monday to punish Illumina with undisclosed “interim measures” over the DNA sequencing company’s “unprecedented” decision to close its $8 billion reacquisition of cancer-testing outfit Grail while an investigation into the deal was still underway.

The European Commission issued a so-called statement of objections that now puts the onus on Illumina and Grail to respond to enforcer complaints, with the added threat of fines over the early close also hanging over their heads.

“Under our rules, companies have to wait for the commission’s clearance before implementing deals that are subject to our review. The standstill obligation is…

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Read more here: Source link